Evidence-based hypertension insights Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality worldwide. Effective management relies on pharmacological interventions that target distinct physiological pathways. Below is a concise, scientifically rigorous overview of three cornerstone classes—ACE inhibitors, CCBs, and ARBs—followed by recent evidence and a quick self‑test.
ACE inhibitors block conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone-mediated sodium retention. Net effects: arterial vasodilation, ↓ systemic vascular resistance, and favorable renal/cardiovascular outcomes—especially in diabetes and chronic kidney disease.
CCBs inhibit L‑type calcium channels in vascular smooth muscle (and, for non‑dihydropyridines, in myocardium). Results: arterial vasodilation, ↓ myocardial contractility, and lower cardiac workload. Dihydropyridines are predominantly vascular; non‑dihydropyridines also reduce heart rate.
ARBs selectively antagonize AT 1 receptors, preventing angiotensin II–mediated vasoconstriction and aldosterone release. Downstream: improved arterial compliance and reduced afterload. Often favored when ACE inhibitors are not tolerated.
A 2025 network meta‑analysis synthesizing 88 RCTs (n=487,076) found that ACE inhibitors, ARBs, and CCBs significantly reduce stroke and all‑cause mortality versus placebo. Combination therapy with an ACE inhibitor + CCB provided superior protection against stroke and cardiovascular mortality compared with monotherapy (Yu et al., PLOS One, 2025).
Reference: Yu D, et al. PLOS One (2025).
In a STEP trial analysis, longer exposure to ARBs and CCBs was associated with ~45% and ~30% reductions, respectively, in composite cardiovascular outcomes, with neutral effects for diuretics and higher risk signals with β‑blockers (likely confounding by indication).
Reference: Peng X, et al. BMC Medicine (2025).
Recent systematic reviews in CKD indicate ACE inhibitors/ARBs reduce proteinuria and slow CKD progression, while CCBs remain effective for blood pressure control—supporting tailored regimens in proteinuric disease.
Reference: Singh A, et al. Cureus (2025).
Sources: Yu D, et al. PLOS One (2025); Peng X, et al. BMC Medicine (2025); Singh A, et al. Cureus (2025).
References:
- Yu D et al. Comparative efficacy of antihypertensive drug classes for stroke prevention: A network meta-analysis. PLOS One. 2025.
- Peng X et al. Impact of antihypertensive drug classes on cardiovascular outcomes: Insights from the STEP study. BMC Medicine. 2025.
- Singh A et al. Comparative efficacy and safety of ACE inhibitors, ARBs, and CCBs in CKD patients. Cureus. 2025.
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Recent articles:
